Tina-quant Lipoprotein(a) Gen.2 Molarity
Lipoprotein, Low-Density, Antigen, Antiserum, Control. 510(k) K241220, from Roche Diagnostics Operations (Indianapolis, IN). Product code DFC, class 2.
As of Nov 20, 2026, K241220 is an FDA 510(k) held by Roche Diagnostics Operations, substantially equivalent on Jan 24, 2025 after 268 days, with no recalls tied to it in FDA's recall database.
- Review time: 268 days
- Recalls: 0
The Tina-quant Lipoprotein (a) Gen.2 Molarity assay is an in vitro test for the quantitative determination of lipoprotein (a) [Lp(a)] in human serum and plasma on cobas c systems. The measurement of Lp(a) is useful in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease risk, when used in conjunction with clinical evaluation and other lipoprotein tests.
- Cobas C Tina-Quant Lipoprotein (A) Gen 2 Assay Model 05852625190; Preciset LP (A) Gen 2 Califrator Set Model 05852641160K122722 · Roche Diagnostics · Nov 29, 2012
- Lipoprotein (a) Molarity AssayK253069 · Diazyme Laboratories, Inc. · Jun 16, 2026
- Lp(a) UltraK211058 · SENTINEL CH. SpA · Dec 22, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- May 1, 2024
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5600
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files